Wave Life Sciences

WVE

Market cap $1.3B

Wave Life Sciences Ltd (NASDAQ:WVE) reported worse-than-expected third-quarter financial results on Monday.

Wave Life Sciences Ltd. ( WVE ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Kyle Moran - CFO & Principal Accounting Officer Erik Ingelsson - Chief Scientific Officer Christopher Wright - Chief Medical Officer Chandra Vargeese - Chief Technology Officer Conference Call Participants Joon Lee - Truist Securities, Inc., Research Division Cheng Li - Oppenheimer & Co. Inc., Research Division Salim Syed Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Madison Wynne El-Saadi - B.

Wave Life Sciences (WVE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.47 per share a year ago.

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models  Activin E reduction in lowest single dose cohort of INLIGHT was sustained through six months, supporting once or twice a year dosing Achieved key AATD treatment goals to recapitulate the MZ phenotype with WVE-006, GalNAc-RNA editing oligonucleotide, in RestorAATion-2 trial: AAT protein exceeded 20 µM during an acute phase response, basal AAT levels reached 13 µM, wild-type M-AAT protein reached 64% of serum AAT, Z-AAT was reduced by 60% WVE-N531 in DMD and WVE-003 in HD remain on track Cash and cash equivalents of $196.2 million as of September 30, 2025; subsequent to quarter-end, additional $72.1 million in ATM proceeds and committed GSK milestones extend expected cash runway into 2Q 2027 Investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass.

CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in November.

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or twice annual dosing

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Wave Life Sciences Ltd. ( WVE ) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics October 29, 2025 10:00 AM EDT Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Christopher Wright - Chief Medical Officer Erik Ingelsson - Chief Scientific Officer Chandra Vargeese - Chief Technology Officer Conference Call Participants Joon Lee - Truist Securities, Inc., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Yun Zhong - Wedbush Securities Inc., Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Cheng Li - Oppenheimer & Co. Inc., Research Division Cha Cha Yang - Jefferies LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division William Maughan Madison Wynne El-Saadi - B.

Wave Life Sciences (WVE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

This press release corrects and replaces the company's press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under “WVE-007  (GalNAc-siRNA)” – “Next steps.”